Literature DB >> 6229551

Assessment of platelet function in patients with Raynaud's syndrome.

R A Hutton, D P Mikhailidis, R M Bernstein, J Y Jeremy, G R Hughes, P Dandona.   

Abstract

Platelet function was studied in 11 patients with Raynaud's syndrome and 11 healthy controls. Platelets obtained from patients with Raynaud's syndrome were significantly more responsive to adrenaline, produced more thromboxane A2, and were resistant to prostaglandin inhibitors (prostacyclin and prostaglandin E1) of platelet aggregation. Platelets from control subjects and patients with Raynaud's syndrome were more resistant to prostaglandin inhibitors when reactions were carried out at 27 degrees C rather than at 37 degrees C. Patients with Raynaud's syndrome also had significantly increased plasma concentrations of beta-thromboglobulin, fibrinogen, and circulating platelet aggregates. In an attempt to elicit local platelet responses, the forearms of control subjects and patients with Raynaud's syndrome were cooled in water tanks and platelet function tests performed before and after cooling. No significant difference in the results was observed. The potential role of platelets in the pathogenesis of Raynaud's syndrome is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6229551      PMCID: PMC498675          DOI: 10.1136/jcp.37.2.182

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  23 in total

1.  A suggested schedule for the rapid investigation of acute haemostatic failure.

Authors:  G I INGRAM
Journal:  J Clin Pathol       Date:  1961-07       Impact factor: 3.411

2.  The effect of cold on platelets. I. Cold-induced platelet aggregation.

Authors:  H E Kattlove; B Alexander
Journal:  Blood       Date:  1971-07       Impact factor: 22.113

3.  Partial purification and characterization of an ADP phosphohydrolase from human plasma.

Authors:  I Holmsen; H Holmsen
Journal:  Thromb Diath Haemorrh       Date:  1971-08-31

4.  Effect of temperature on reactivity of isolated cutaneous veins of the dog.

Authors:  P M Vanhoutte; J T Shepherd
Journal:  Am J Physiol       Date:  1970-01

5.  Hypothermia and pancreatitis.

Authors:  D P Mikhailidis; R A Hutton; J Y Jeremy; P Dandona
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

6.  Microdetermination of adenosine diphosphate and adenosine triphosphate in plasma with firefly luciferase system.

Authors:  H Holmsen; I Holmsen; A Bernhardsen
Journal:  Anal Biochem       Date:  1966-12       Impact factor: 3.365

7.  Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial.

Authors:  J J Belch; P Newman; J K Drury; F McKenzie; H Capell; P Leiberman; C D Forbes; C R Prentice
Journal:  Lancet       Date:  1983-02-12       Impact factor: 79.321

8.  Treatment of Raynaud's phenomenon with the 5-HT2-receptor antagonist ketanserin.

Authors:  E Stranden; O K Roald; K Krohg
Journal:  Br Med J (Clin Res Ed)       Date:  1982-10-16

9.  The application of polyethylene glycol to radioimmunoassays used in haemostasis.

Authors:  B J Woodhams; P B Kernoff
Journal:  Thromb Res       Date:  1983-02-01       Impact factor: 3.944

10.  Prostaglandin E1 in severe Raynaud's phenomenon.

Authors:  B J Pardy; M C Hoare; H H Eastcott; C C Miles; T N Needham; T Harbourne; B W Ellis
Journal:  Surgery       Date:  1982-12       Impact factor: 3.982

View more
  10 in total

1.  Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon.

Authors:  D P Mikhailidis; R A Hutton; J Y Jeremy; P Dandona
Journal:  Br Med J (Clin Res Ed)       Date:  1986-05-31

2.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Authors:  J J Belch; A A Zoma; I M Richards; K McLaughlin; C D Forbes; R D Sturrock
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  The effect of nisoldipine on whole blood platelet aggregation in patients with Raynaud's phenomenon.

Authors:  J L Francis; O S Roath; V F Challenor; D G Waller
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

4.  Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; K Illingworth; A Blann; C R Hay; S Hollis; M I Jayson
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

5.  Fibrinogen mediated activation of platelet aggregation and thromboxane A2 release: pathological implications in vascular disease.

Authors:  D P Mikhailidis; M A Barradas; A Maris; J Y Jeremy; P Dandona
Journal:  J Clin Pathol       Date:  1985-10       Impact factor: 3.411

Review 6.  Serotonin and the vascular system. Role in health and disease, and implications for therapy.

Authors:  D S Houston; P M Vanhoutte
Journal:  Drugs       Date:  1986-02       Impact factor: 9.546

7.  Abnormal platelet aggregation in patients with Raynaud's phenomenon.

Authors:  M L Biondi; B Marasini
Journal:  J Clin Pathol       Date:  1989-07       Impact factor: 3.411

Review 8.  Raynaud's phenomenon: new aspects of pathogenesis and the role of nailfold videocapillaroscopy.

Authors:  Anna Kuryliszyn-Moskal; Jacek Kita; Anna Hryniewicz
Journal:  Reumatologia       Date:  2015-05-18

Review 9.  Raynaud's Phenomenon: Reviewing the Pathophysiology and Management Strategies.

Authors:  Iqra Nawaz; Yashfa Nawaz; Eisha Nawaz; Muhammad Romail Manan; Adil Mahmood
Journal:  Cureus       Date:  2022-01-28

10.  Clopidogrel treatment may associate with worsening of endothelial function and development of new digital ulcers in patients with systemic sclerosis: results from an open label, proof of concept study.

Authors:  Konstantinos Ntelis; Vasileios Gkizas; Alexandra Filippopoulou; Periclis Davlouros; Dimitrios Alexopoulos; Andrew P Andonopoulos; Dimitrios Daoussis
Journal:  BMC Musculoskelet Disord       Date:  2016-05-17       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.